Inflammaging: How Chronic Inflammation Affects Longevity

Inflammation is part of normal human physiology. It helps us respond to infection, repair damaged tissue, and recover from injury. Problems can develop when inflammatory activity persists beyond its useful role or becomes chronically elevated over time.

The term inflammaging describes the chronic, low-grade inflammatory state that often accompanies aging. It has been associated with cardiovascular disease, metabolic dysfunction, immune aging, frailty, neurodegenerative disease, and other conditions that become more common later in life.

Research published over the past several years has also made the picture more nuanced. Inflammaging is not a single process that occurs in exactly the same way in everyone. Genetics, lifetime infections, visceral adiposity, metabolic health, cellular senescence, environmental exposures, sleep, diet, physical activity, and socioeconomic conditions can all influence an individual's inflammatory profile.

One-Minute Read

Inflammaging refers to persistent, low-grade inflammatory activity associated with aging. It is an important area of longevity research because chronic inflammatory signaling overlaps with many of the biological processes that influence cardiovascular health, metabolism, immune function, muscle, brain health, and physical resilience.

It is also more complicated than simply having “too much inflammation.” Acute inflammation is necessary for healing and immune defense. The body must also regulate that response, clear damaged cells and debris, repair tissue, and restore normal function. This resolution phase is an active biological process involving immune cells, signaling proteins, lipid mediators, and other regulatory systems.

There is no single blood test that diagnoses inflammaging, and there is no single supplement that corrects it. At HormoneSynergy®, we look for the underlying contributors, including metabolic dysfunction, visceral fat, smoking, inadequate sleep, chronic disease, infection, poor fitness, and other sources of inflammatory stress. Resolution-focused nutrition and specialized marine lipid supplements may have a role for selected individuals, but they remain supportive tools within a much broader longevity strategy.

What Inflammaging Actually Means

Inflammaging was originally described as the chronic, systemic, low-grade inflammatory state that tends to increase with age even in the absence of an obvious acute infection. Researchers have since identified multiple biological processes that can contribute to it, including cellular senescence, altered immune function, mitochondrial dysfunction, metabolic disease, adipose tissue dysfunction, changes in the gut microbiome, and repeated exposure to infectious and environmental stressors.

A 2025 review in Nature Aging described inflammaging as a major risk factor for age-related disease and a point where several mechanisms of aging converge. The same review emphasized an equally important point: there is considerable variation from person to person. Inflammatory aging reflects a lifetime of biology and exposure rather than chronological age alone.

This helps explain why two people of the same age can have very different metabolic health, cardiovascular risk, physical function, and inflammatory profiles.

Inflammation Is Not Always Harmful

Inflammation is often discussed as though the goal should be to eliminate it. That would not be desirable. An appropriate inflammatory response is essential for immune defense, wound healing, exercise adaptation, and tissue repair.

The clinical concern is persistent or dysregulated inflammation. Chronic inflammatory activity can alter endothelial function, insulin signaling, immune function, tissue repair, and cellular metabolism. Over time, those effects may contribute to the development or progression of age-related disease.

This is also why anti-inflammatory medications should not be portrayed simply as a failure to address the underlying biology. NSAIDs, corticosteroids, biologic medications, and other anti-inflammatory treatments have important and sometimes lifesaving roles when appropriately prescribed. Inflammation control and inflammation resolution are related concepts, but they are not interchangeable treatment strategies.

Resolution Is an Active Biological Process

One of the important advances in inflammation research has been the recognition that resolution is actively regulated. The immune response does not simply fade away when the initial stimulus disappears.

During normal resolution, immune-cell behavior changes, damaged cells and cellular debris are cleared, inflammatory signals decline, and tissue repair proceeds. Several families of signaling molecules participate in this process, including proteins and lipid mediators.

Specialized pro-resolving mediators, or SPMs, are one group of lipid signaling molecules involved in resolution biology. Resolvins, protectins, maresins, and lipoxins belong to this family. Their biology is well established experimentally and continues to be studied in cardiovascular disease, immune regulation, pain, infection, and tissue repair.

SPMs are important, but they should not be presented as the entire resolution system. Resolution involves numerous interacting immune cells and signaling pathways, and researchers are still working out how best to translate that biology into clinical treatment.

For a closer review of the human evidence and the distinction between true downstream SPMs and compounds such as 18-HEPE, 17-HDHA, and 14-HDHA, see our guide to Specialized Pro-Resolving Mediators and inflammation resolution.

Why Inflammaging Matters for Cardiovascular and Metabolic Health

The relationship between inflammation, metabolism, and cardiovascular disease is particularly well established. Visceral adipose tissue can produce inflammatory signaling molecules, while insulin resistance and metabolic dysfunction can further alter immune activity. The relationship can become bidirectional, with metabolic dysfunction contributing to inflammation and inflammatory signaling making metabolic regulation more difficult.

Inflammaging has also become an important area of cardiovascular research. Chronic vascular inflammation is involved in atherosclerosis and other forms of cardiovascular aging, although cardiovascular risk still needs to be evaluated through established measures such as blood pressure, ApoB-containing lipoproteins, glucose metabolism, smoking exposure, kidney function, body composition, family history, and appropriate imaging rather than through inflammation alone.

The same systems overlap with muscle health, frailty, and immune aging. Loss of muscle, reduced activity, excess visceral fat, poor metabolic health, and chronic inflammatory signaling can reinforce one another as people age.

This interconnected biology is discussed further in our guide to immunometabolism.

Inflammaging and the Brain

Systemic inflammation is also being studied as one contributor to brain aging and neurodegenerative disease. Immune signaling outside the brain can influence neuroimmune activity, while vascular disease, insulin resistance, sleep disorders, infection, and metabolic dysfunction can contribute to both systemic inflammation and cognitive risk.

This does not mean that inflammation alone causes Alzheimer's disease or other forms of dementia. Neurodegenerative disease is multifactorial, and the relationships among immune aging, vascular risk, protein aggregation, metabolism, genetics, and environmental exposures remain active areas of research.

The practical implication is that brain health should not be separated from cardiovascular and metabolic health. The factors that influence inflammatory biology often overlap with the factors already known to affect cognitive aging.

Can We Measure Inflammaging?

There is currently no single validated clinical test that tells us whether someone “has inflammaging.” Researchers are studying combinations of inflammatory proteins, immune-cell patterns, metabolic markers, epigenetic measures, and other biomarkers, but no universal inflammaging score has become standard clinical practice.

High-sensitivity C-reactive protein, or hsCRP, can provide useful information about systemic inflammation and has an established role in cardiovascular risk assessment. Even hsCRP, however, is nonspecific. Infection, injury, autoimmune disease, obesity, smoking, and numerous other conditions can influence the result.

Other indices, including the Systemic Immune-Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI), are being studied using information already contained in a complete blood count. These measures are interesting but remain emerging risk markers rather than established treatment targets.

Our review of SII, SIRI, and CBC-based inflammation markers explains where that research currently stands.

What We Look for Clinically

When inflammatory markers remain elevated, the useful question is usually not how to lower the marker as quickly as possible. The first step is understanding what may be contributing to it.

• Visceral adiposity, insulin resistance, or poor glucose regulation
• Smoking or other chronic environmental exposures
• Poor sleep or untreated sleep apnea
• Low physical activity and loss of muscle
• Acute or chronic infection
• Autoimmune or inflammatory disease
• Periodontal disease and other sources of chronic inflammatory signaling
• Poor dietary quality or excessive alcohol exposure
• Medication effects and other medical conditions

The appropriate response depends on the cause. In some cases, improving body composition, physical activity, sleep, diet, or metabolic health may reduce inflammatory burden. In others, persistent inflammation may warrant additional medical evaluation rather than another supplement.

Where Resolution-Focused Supplements Fit

Resolution biology has created understandable interest in nutritional strategies intended to support pro-resolving pathways. Marine lipid concentrates standardized to compounds such as 18-HEPE, 17-HDHA, and 14-HDHA have been studied in small human trials, particularly for pain and joint-related outcomes.

The evidence is encouraging enough that Dr. Kathryn Retzler may consider this type of support for selected patients, but it is not evidence that an SPM-focused supplement prevents cardiovascular disease, protects against dementia, reverses inflammaging, or extends lifespan.

RetzlerRx® Synergy SPM provides a fractionated marine lipid concentrate standardized to 18-HEPE, 17-HDHA, and 14-HDHA. When used, it is one component of a larger plan rather than a substitute for identifying and addressing the factors contributing to chronic inflammatory activity.

The HormoneSynergy® Perspective

Inflammaging is useful because it connects several areas of aging biology that were once discussed separately. Metabolism, visceral fat, immune function, cellular senescence, cardiovascular health, infection, environmental exposures, and physical resilience can all influence inflammatory signaling over time.

It is less useful when the term becomes a diagnosis applied to every symptom or a justification for an expanding list of anti-inflammatory medications or supplements.

At HormoneSynergy®, our approach is to evaluate inflammation in context. We consider established cardiovascular and metabolic risk factors, body composition, lifestyle, symptoms, medications, laboratory trends, and medical history before deciding whether an inflammatory finding requires treatment, further investigation, or simply continued observation.

Inflammation resolution is an important part of that biology. It belongs within a broader model of preventive longevity medicine rather than replacing it.

Frequently Asked Questions

What is inflammaging?

Inflammaging describes chronic, low-grade systemic inflammatory activity associated with aging. It is influenced by immune aging, cellular senescence, metabolic health, visceral adiposity, infections, environmental exposures, lifestyle, genetics, and other factors.

Does everyone develop inflammaging?

No. Inflammatory patterns vary substantially among individuals and populations. Recent research emphasizes that inflammaging is heterogeneous and reflects a combination of biological aging and lifelong exposures rather than chronological age alone.

Is inflammation always harmful?

No. Acute inflammation is necessary for immune defense, healing, and tissue repair. The concern is inappropriate, persistent, or dysregulated inflammatory activity.

Can hsCRP diagnose inflammaging?

No. hsCRP is a useful marker of systemic inflammation and cardiovascular risk, but it is nonspecific and can be influenced by infection, injury, obesity, autoimmune disease, smoking, and other conditions. There is currently no single diagnostic test for inflammaging.

What is inflammation resolution?

Resolution is the regulated process by which an inflammatory response moves toward completion. It involves changes in immune-cell activity, clearance of damaged cells and debris, tissue repair, and multiple signaling systems, including specialized pro-resolving mediators.

Can supplements reverse inflammaging?

No supplement has been shown to reverse inflammaging or extend lifespan by correcting inflammation. Certain supplements may support specific nutritional or physiological pathways, but persistent inflammatory findings should be interpreted in the context of the individual's overall health and potential underlying causes.

Are SPM supplements proven to prevent age-related disease?

No. The biology of specialized pro-resolving mediators is well established, but human trials of oral SPM-enriched marine lipid products remain relatively small. Current research does not show that these supplements prevent cardiovascular disease, dementia, or other major age-related diseases.

Selected Research

Franceschi C, Olivieri F, Moskalev A, et al. Toward precision interventions and metrics of inflammaging. Nature Aging. 2025;5:1441-1454. Read the review.

Bracken OV, De Maeyer RPH, Akbar AN. Enhancing immunity during ageing by targeting interactions within the tissue environment. Nature Reviews Drug Discovery. 2025;24:300-315. Read the review.

Fredman G, Serhan CN. Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease. Nature Reviews Cardiology. 2024;21:808-823. Read the review.

Spray L, et al. Cardiovascular inflammaging: Mechanisms, consequences, and therapeutic perspectives. Cell Reports Medicine. 2025. PubMed.

Educational Note

This article is for educational purposes and is not intended to diagnose, treat, cure, or prevent disease. Inflammatory biomarkers should be interpreted in the context of symptoms, medical history, medications, acute illness, metabolic and cardiovascular risk, and trends over time. Persistent or unexplained inflammation may require medical evaluation.